“This milestone reflects our commitment to expanding access to high-quality injectable products that support healthcare providers and their patients,” said Tom DeStefano, Vice President of Specialty Sales.
Nitazoxanide Tablets are antiprotozoal indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
The launch expands Camber’s hospital and acute care products and provides healthcare providers access to a widely used neuromuscular blocking agent for anesthesia and critical care.
By expanding treatment options and increasing availability of essential therapies, Camber continues to support healthcare providers, pharmacies, and patients across the country.
Camber Pharmaceuticals aims to expand in the U.S. generics market. President Kon Ostaficiuk highlights a strategy focused on scale, speed, and competitiveness.
New launches emphasize Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
New launches of Plerixafor Injection, Baclofen Tablets, Fluvoxamine Maleate ER Capsules, and Olmesartan Hydrochlorothiazide Tablets.
Pomalidomide capsules are available in 1 mg, 2 mg, 3 mg, and 4 mg strengths in bottles of 21 capsules.
Sodium Oxybate Oral Solution 0.5 g/mL is available in 180 mL bottles and is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy.
Voriconazole for Oral Suspension treats yeast and fungal infections in adults and children 2 years and older, especially in cases of intolerance or resistance to other treatments.
Spironolactone Tablets are indicated for treatment of Heart Failure, Hypertension, Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome, and Primary Hyperaldosteronism.
Camber’s year featured broad generic launches, specialty and oncology introductions, emphasizing access, affordability, and supply reliability in the U.S.
“This award is a direct result of strong collaboration and shared accountability,” said Stu Messinger, Director of National Accounts.
Camber Pharmaceuticals continues to strengthen its range of treatment options.
The tablets are indicated for the acute treatment of migraine, with or without aura, in adults.
Abacavir/Lamivudine Tablets, USP are indicated for treating HIV-1 infection.
